PTI-808
Idiopathic Pulmonary Fibrosis · ANZCTR
Clinical trials
1
Mechanism
ANZCTR
Developer
Proteostasis Therapeutics, Inc.
Overview
PTI-808 is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis, acting via anzctr. It appears in 1 tracked IPF clinical trial.
PTI-808 clinical trials
Explore related
Medical disclaimer. This page summarizes research about PTI-808 for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.